Contact Us

    CORE ANXIETY AND DEPRESSION REPORT (15 GENES)

    Core+Gen

     

    This report looks at a subset of our 24 gene panel and is specific to the treatment of anxiety, depression and related disorders. The information provided by this report is designed to help clinicians make more informed treatment decisions, and to help avoid the painful process of trial and error.*

     

    square test all parts on black2

    Includes:
    Our anxiety and depression focused test – 15 genes
     
    Genetic implications for 130 mental health medications
     
    3 Report Summary Views for your Clinicin
     
     
    Genomind® Professional PGx Rx MetaType™ Card
     
    Your Gene Results are Good for Life

    FSA/HSA Eligible
     
    FOR CLINICIANS FOR YOU & YOUR
    FAMILY
    Order Test Kits Get the Test

     

    Genes We Analyze

    Each report looks at both Pharmacodynamic and Pharmacokinetic .

    Pharmacodynamic: this refers to the effect that a drug has on your body. For example, a drug might bind to a certain receptor in your brain, or you might make a certain protein that increases your risk of a drug induced rash.  These are all pharmacodynamic parameters.   

     

    Pharmacokinetic: this refers to the effect that your body has on a drug.  For example, your body can absorb and metabolize certain drugs at different speeds which can help personalize medication dosage.  These speeds are different between people and are known as pharmacokinetic parameters. 

     

     

     

    Images below are a sample of the report and do not show the full report.

    genes-analyzed-092719-1-1024x699

    Download Gene Table

    Gene Variations Summary

    The gene variations report provides the patient genotype for each of the gene variants on our panel. The color coded genotype reflects the patients inherited alleles, or variants, at a particular location within the tested gene. The report also provides specific therapeutic guidance related to certain medications, or non-drug options like exercise  or TMS.



    pharm-gene-var-092519-1-1024x699

     



    Medication falls into two categories:
    interaction-cat1

    Gene Drug Interaction Summary

    Each patient report includes a gene-drug interaction summary. The gene-drug interaction summary provides information about how the patient’s genetic profile interacts with medications commonly used in psychiatry. This summary table lists medications in alphabetical order by generic name and drug class.



    gdig-092519-1-1024x699

    Diagnosis-Specific Summary

    Diagnosis-specific Summary Pages will provide a visual plot of drugs and augmentation strategies for a particular condition. The medication position will shift left or right based on known gene-drug interactions.

    • Alert/Caution: Drugs will shift to the left if a patient has genetic variations that may reduce efficacy, increase likelihood of side effects or alter drug metabolism/absorption.
    • Standard Options: Drugs that are not shifted indicate that there are no significant gene-drug interactions for the patient.
    • PGx Guided Options: Drugs will be shifted to the right if the patient has genetic variations that may increase likelihood of efficacy or tolerability.



    summary-092519-1-1024x699


    Genomind Professional PGx Rx MetaType Card


    metatype card with express

    Unique to Genomind, every test comes with an Rx MetaType Card that our expert team designed. To learn more CLICK HERE.

    *Genomind Professional PGx Express™ CORE Anxiety and Depression Report™ is intended to provide genetic information to healthcare professionals which may aid in the selection of appropriate medications for individuals with mental illness and other brain disorders. This 15 gene report is designed to be adjunctive to a complete patient assessment, including but not limited to proper diagnosis, clinical history, assessment of concomitant co-morbidities and medications, family history, and other factors. Additional information may be found by consulting the Prescribing Information of various FDA-approved medications, or other relevant resources such as the FDA’s Table of Pharmacogenomic Biomarkers in Drug Labeling.